BillionToOne UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
With UBS, it is my pleasure to welcome Oguzhan Atay, co-founder and Chief Executive Officer of BillionToOne. Thank you for being here. I appreciate you making the trip. BillionToOne brings a compelling scientific foundation to important clinical questions, from prenatal screening with Unity to cancer care with Northstar. Lots to talk about, lots of exciting things going on in the company. Today, what we are going to do is we are really going to explore the growth runway, adoption, and really the balance between investment in growth, investment in science, and profitability. In terms of just essentially the discussion arc for today, I want to spend some time on platform differentiation. I want to talk a little bit about the quarter. Then we will go product category by product category. We will go Unity, Northstar, and then we will wrap up with some financials. That is the roadmap. Just to start off, high level, what unmet need inspired BillionToOne?
What inspired you to advance the science, advance the technology, and where does the QCT backbone that supports precise quantification create the greatest clinical and economic advantage relative to other solutions that are out there?
Cell-free DNA is a truly remarkable biomarker. It is the microcosm of the entire body, but it is also a very rare entity biomarker. What we realized was that as a scientist, we were seeing how, and maybe for the first time, an academic idea can turn into a very impactful clinical outcome very quickly. I was at Stanford, and looking at the evolution of cell-free DNA field, seeing firsthand how an academic research can impact millions of lives, change standards of care. We started looking into what more cell-free DNA can be used for. We realized that the most common genetic disorders in the world are not trisomies, are not Down syndrome or aneuploidies. They are these single gene conditions, and in particular sickle cell disease and beta thalassemia.
We realized that to be able to detect sickle cell disease and beta thalassemia and other single gene conditions directly from a maternal blood sample, you have to get down to single molecule level sensitivity, and you need to remove all sorts of other noise. That is what QCT technology allows us to do. Of course, as soon as we built the technology, we knew how it would be transformative, not just for prenatal testing, but across the board for cell-free DNA testing. It can unlock tremendous clinical value, especially as the problems become more difficult. As we go from large chromosomal abnormalities to single gene conditions, and from late-stage cancers to early-stage cancers and even early detection, the problem is no longer the signal. The problem is the noise.
We see this from actually the different approaches that different companies take to these more difficult technical problems. If you are looking at something that is 0.01% of the total DNA or lower, it is no longer about trying to sequence more. It's no longer about trying to look at more and more locations, because you are not limited by the signal. You are limited by the noise that that process brings in. This is why, regardless of what approaches that the others are taking, if you look at the clinical results for tissue-free MRD or early detection, performances are very similar, and they are not enough. They are not at the levels that we want them to be for them to be truly standards of care.
This is where I think QCT, by being able to reduce the noise, allows us to tackle those clinical problems that no brute force, kind of let's sequence as much as possible approach can solve. In simpler problems, it allows us to have industry-leading low level of COGS. The advantage of QCT technology is when we are solving a problem that another methodology can solve, for instance, either directly or indirectly, the COGS of solving it in other ways is going to be substantially higher than what we can do it for. But as we go into more and more difficult problems, especially in cancer, it's not even just a COGS question. It becomes much more of a capability question.
Right. Differences in limit of detection, the resolution that you can look at things with. It's interesting, a different discussion earlier today, and again, I'm not a scientist, but I've looked at a lot of papers. I play one on T.V. No. When you look at a lot of the cell-free DNA approaches, you do start to see certain areas where some of the technologies that have been advanced, some of the more traditional approaches, if you can talk about it that way, given we're still at a pretty early stage in the industry. The biology does seem to lead you to sort of the same conclusions in terms of what the limit of what you can do is, toggling between sensitivity and specificity. What you're describing is an approach that obviously, because of how it treats noise, can basically do better than those approaches.
But it does seem like some of those approaches are hitting their ceiling. It doesn't sound like you feel like you're at a point where you're hitting the limit of what you can do with your approach, factoring in the biology.
Is that fair? That is fair.
I mean, if you think about tumor-informed MRD as a category, why does anyone do tumor-informed MRD? The concept of tumor-informed MRD is that when you sequence the cell-free DNA, you see real mutations, but you see all sorts of PCR errors, amplification errors, sequencing errors. It becomes very difficult to differentiate what is real or what is not.
Right. That is the sensitivity-specificity trade-off in tissue-free MRD and early detection, right?
If you call them, your sensitivity increases, but your specificity decreases. This is why there are so many more tumor-informed approaches, because it solves the noise problem. If you sequence the tissue to begin with, now you know which mutations are real, so you can just look at those mutations in cell-free DNA. But of course, tumor-informed MRD has logistical challenges, other problems. Of course, you can't do tumor-informed early detection.
Right. Right? Right. You need to do it in a tissue-free manner.
This is where our technology, I think, is going to shine the most, because we don't even have to compete with the tumor-informed approaches.
One more high-level question, and this is really interesting. We have talked about, and we are going to go into more detail about your journey in reproductive health, your advancements in cancer. With this approach, logically, there are other areas you could participate. In the long term, again, you have a lot to work with what you have now, but the QCT, the approach lends itself well to other areas, presumably including screening. Is that something on your long-term roadmap?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
